Does Rosuvastatin Prevent Heart Disease in Healthy People with Intermediate Risk?
Slightly. In the HOPE-3 trial, 3.7% of people taking rosuvastatin had a cardiovascular death, nonfatal heart attack, or nonfatal stroke over a median of 5.6 years, compared with 4.8% on placebo. That is an absolute reduction of about 1.1 percentage points, or about 1 in 91 people treated to prevent one event. In relative terms, it is a 24% lower risk. The trial randomized 12,705 people in 21 countries who had no cardiovascular disease.
Dr. Kumar’s Take:
The HOPE-3 trial found that the absolute benefit of rosuvastatin (10 mg daily) was small in people without prior heart disease: only 1 fewer event per 91 people treated over 5.6 years. In relative terms, that is a 24% reduction. Those with a clear reason to take or avoid statins were excluded, and the study was funded by the Canadian Institutes of Health Research and AstraZeneca, the drug’s maker, which raises concerns about bias. In this trial, the benefit in absolute terms was small, and any decision should be individualized.
Brief Summary:
This large, randomized controlled trial studied 12,705 people across 21 countries who had risk factors for heart disease but no prior cardiovascular events. Participants were given either rosuvastatin (10 mg/day) or a placebo and followed for 5.6 years.
Key Findings:
✔ Rosuvastatin lowered LDL cholesterol by 26.5%.
✔ Absolute risk reduction: 1.1 percentage points (3.7% vs. 4.8%; NNT = 91).
✔ Relative risk reduction: 24%.
✔ More muscle symptoms (5.8% vs. 4.7%) and cataract surgeries (3.8% vs. 3.1%).
✔ No increase in diabetes or cancer.
Study Design:
This was a randomized, placebo-controlled study. Participants were men over 55 and women over 60 with at least one additional cardiovascular risk factor. People with a clear indication or contraindication for statins were excluded.
Results:
First Primary Outcome (CV Death, MI, Stroke)
- Rosuvastatin: 3.7% had an event
- Placebo: 4.8% had an event
- Absolute risk reduction (ARR): 1.1%
- Relative risk reduction (RRR): 24%
- NNT: 91
Expanded Outcome (Above + Cardiac Arrest, Heart Failure, Revascularization)
- Rosuvastatin: 4.4% had an event
- Placebo: 5.7% had an event
- ARR: 1.3%
- RRR: 25%
- NNT: 77
Limitations and Considerations
- People with a clear contraindication to statins were excluded, so real-world results may differ.
- Absolute risk reduction was modest, meaning the benefit per person is small.
- The Canadian Institutes of Health Research and AstraZeneca funded the study. AstraZeneca makes rosuvastatin.
Related Studies and Research
Rosuvastatin, CRP, and the JUPITER Trial: Examines the JUPITER trial findings on rosuvastatin and C-reactive protein in primary prevention.
Statins for Healthy Men: A Review: Investigates the risks and benefits of statin therapy in men without established heart disease.
Statins and Neuromuscular Side Effects: Analyzes the potential neuromuscular complications associated with statin use.
Frequently Asked Questions
Should you take rosuvastatin for prevention?
In this trial, 91 people had to take rosuvastatin for about 5.6 years to prevent one cardiovascular event. Muscle symptoms and cataract surgery were also more common on the drug. Whether that trade-off makes sense depends on your own risk and preferences, and is a decision to make with your own doctor.
What about side effects?
Muscle symptoms were slightly more common, and cataract surgeries were slightly higher in the rosuvastatin group. However, no increase in diabetes or cancer was seen.
Why does AstraZeneca’s funding matter?
Industry-funded studies sometimes show more favorable results. AstraZeneca makes rosuvastatin and co-funded this trial, which is worth keeping in mind when reading the results.
Conclusion
In the HOPE-3 trial, rosuvastatin 10 mg daily lowered cardiovascular events from 4.8% to 3.7% over 5.6 years in intermediate-risk people without heart disease. In absolute terms, the benefit was small: about 1 in 91 people treated avoided an event. Muscle symptoms and cataract surgery were more common on the drug, and real-world results may differ. If you’re weighing a statin, these absolute numbers are the ones to discuss with your doctor.
